New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
about
Juvenile myelomonocytic leukemia: molecular pathogenesis informs current approaches to therapy and hematopoietic cell transplantationPharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia.Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamideMulti-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioningOnce daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.Multicenter phase II study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG).Busulfan in hematopoietic stem cell transplantationThe histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.Feasibility of non-TBI conditioning with busulfan and fludarabine for allogeneic stem cell transplantation in lymphoid malignancyBusulfan plus fludarabine compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with hematologic neoplasms: a meta-analysis.Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and muLow non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial.Fludarabine and busulfan as a reduced-toxicity myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation for acute leukemia patientsDoes anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia WPharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan.Substitution of cyclophosphamide in the modified BuCy regimen with fludarabine is associated with increased incidence of severe pneumonia: a prospective, randomized study.Comparable analysis of outcomes for allogeneic peripheral blood stem cell transplantation from matched related and matched unrelated donors in acute myeloid leukemia.Early onset of acute GVHD indicates worse outcome in terms of severity of chronic GVHD compared with late onset.Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients.Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis.Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies.Fatal BK virus pneumonia following stem cell transplantation.Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity.Chimerism in Myeloid Malignancies following Stem Cell Transplantation Using FluBu4 with and without Busulfan Pharmacokinetics versus BuCy.Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission.A novel reduced-intensity umbilical cord blood transplantation using a recombinant G-CSF combined with high-dose Ara-C for active myeloid malignancies.Single center retrospective analysis of BU-based conditioning regimens in allogeneic transplantation.
P2860
Q26851000-40052C89-EC54-4AD6-92C9-0ACAE018356CQ34220717-85107755-50CC-4080-A6BF-5873F53D3163Q34316871-B899DD94-3FF6-4CF2-81C7-6260120A2C45Q34402494-889A3909-AB50-4AF0-BDB4-16155CEB0094Q34505185-229ECEBC-2E5C-46FA-B1CD-40C4DBDB8370Q34544439-0EAC9D15-14BE-4C4F-AC97-0D1FFB74D492Q34668052-89DC289F-421F-4E01-8488-633C6D8779B6Q35060679-82D8FA34-C8E5-48B0-AC37-2AF06D84028BQ35809873-50E25DBA-9489-4CD5-9E2F-AC194A8F5D77Q36182610-FC20C710-3008-4C56-A2FF-9E7A6D56B723Q36608468-A6C7A6AD-D453-4C91-B4E7-B14EF6B78A3CQ36715911-D4963FEE-DE3F-48A2-92AA-89C00A323623Q36742108-FDA0EBE1-DAD9-4897-92DB-A84F12BD9398Q37081469-3F145696-5DFF-416E-B25E-513CC210F0D2Q37140698-C6B86D96-950A-403B-A86D-39E20EAC36E0Q37602434-60E12634-4CF5-42A3-BAF8-1148A3B729D5Q38060264-27F18F20-4C05-42EE-901B-937FFFADAF1CQ38441123-7F4E695B-C14C-4F48-9F18-27E261B7FDD6Q38467711-662CD1F7-5C67-4DE3-A63C-46456288887EQ38488050-67E5EEAF-97BC-431C-902B-E186867AA9F0Q38496996-A5DB5EC6-FE96-4CC5-98AB-791AAB2F9066Q38604900-00062570-DCD9-454F-A3AD-4B81CEB25AB4Q39632454-5E359802-D728-4A6D-999E-A7987383D378Q42175192-C51193A0-4091-4A40-B618-046EE615843BQ45354654-E768B4B5-976C-46B9-976D-B9A5CAACEB39Q47124626-095C4FF5-DF69-4A2A-AF68-E5406751CD25Q47144269-68D49CB1-01C0-4221-9A99-833677BEE2F3Q49790702-BCC55F21-F058-4162-9DD6-41120993F623Q53057732-BC5DB2F6-7697-4E3B-BB29-C6181C05F921Q54051617-66246E78-08B0-4B48-B7D5-8063919D8F98
P2860
New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
New myeloablative conditioning ...... tation: comparison with BuCy2.
@en
type
label
New myeloablative conditioning ...... tation: comparison with BuCy2.
@en
prefLabel
New myeloablative conditioning ...... tation: comparison with BuCy2.
@en
P2093
P356
P1476
New myeloablative conditioning ...... tation: comparison with BuCy2.
@en
P2093
P2888
P304
P356
10.1038/SJ.BMT.1705770
P407
P577
2007-07-16T00:00:00Z
P5875
P6179
1049898813